New York State Common Retirement Fund Decreases Stake in TransMedics Group, Inc. $TMDX

New York State Common Retirement Fund lowered its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 89.8% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 15,240 shares of the company’s stock after selling 134,406 shares during the quarter. New York State Common Retirement Fund’s holdings in TransMedics Group were worth $1,710,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of the business. TD Waterhouse Canada Inc. lifted its holdings in TransMedics Group by 26.5% during the third quarter. TD Waterhouse Canada Inc. now owns 601 shares of the company’s stock worth $69,000 after acquiring an additional 126 shares during the period. Federated Hermes Inc. purchased a new stake in shares of TransMedics Group during the 3rd quarter valued at $672,000. Phoenix Financial Ltd. raised its stake in shares of TransMedics Group by 190.6% during the 3rd quarter. Phoenix Financial Ltd. now owns 5,903 shares of the company’s stock worth $663,000 after purchasing an additional 3,872 shares during the period. Pilgrim Partners Asia Pte Ltd purchased a new position in shares of TransMedics Group in the 3rd quarter worth about $40,000. Finally, Whittier Trust Co. of Nevada Inc. grew its position in TransMedics Group by 981.0% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after buying an additional 206 shares during the period. 99.67% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director David Weill sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total transaction of $693,200.00. Following the completion of the transaction, the director owned 12,134 shares of the company’s stock, valued at approximately $1,682,257.76. The trade was a 29.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Anil P. Ranganath sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the sale, the insider directly owned 13,955 shares in the company, valued at $2,026,545.10. This trade represents a 17.69% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 8,920 shares of company stock valued at $1,257,310. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Trading Up 4.2%

NASDAQ:TMDX opened at $135.06 on Monday. TransMedics Group, Inc. has a 1 year low of $62.07 and a 1 year high of $156.00. The stock’s fifty day moving average price is $133.12 and its two-hundred day moving average price is $124.60. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. The company has a market cap of $4.62 billion, a P/E ratio of 54.68 and a beta of 2.06.

Analysts Set New Price Targets

TMDX has been the topic of several research reports. Jefferies Financial Group started coverage on shares of TransMedics Group in a research report on Monday, October 13th. They issued a “buy” rating and a $145.00 price objective on the stock. Needham & Company LLC lifted their price target on shares of TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Canaccord Genuity Group increased their price objective on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Morgan Stanley raised their target price on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $144.25.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.